Preliminary analysis of combined romosozumab and denosumab versus teriparatide and denosumab on bone mineral density
{{output}}
Objectives: The effectiveness of combining romosozumab (ROMO) with denosumab (Dmab) remains uncertain. We compare the six-month effects of Dmab plus monthly ROMO versus Dmab plus daily teriparatide (TPTD) on bone mineral density ... ...
